Abstract
A frequent dose-limiting effect of irinotecan (CPT-11) is its gastrointestinal toxicity (diarrhea), which is thought to be related to biliary excretion of CPT-11 and its metabolites. Accordingly, we have investigated the mechanism of biliary excretion of these compounds. In vivo pharmacokinetic studies revealed that the biliary excretion of the four anionic forms of CPT-11 and its metabolites was reduced in Eisai hyperbilirubinemic rats, which carry a mutation of the hepatic canalicular multi-specific organic anion transporter (cMOAT) gene. The protein encoded by this gene is expressed on the bile canalicular membrane and is responsible for the transport of organic anions into bile. Detailed analysis using isolated liver bile canalicular membrane vesicles to identify transport systems showed that cMOAT is responsible for biliary excretion of the low-affinity component of the carboxylate form of CPT-11 and the high-affinity component of both the lactone and carboxylate forms of SN-38 glucuronide. The carboxylate form of SN-38 is transported by cMOAT alone. Transport of the high-affinity component of CPT-11 was inhibited by verapamil and PSC-833, but their effect on the transport of its low-affinity component was minimal. In addition, ATP dependence in the uptake of CPT-11 by membrane vesicles obtained from a P-glycoprotein (P-gp)-overexpressing cell line was observed. Thus P-gp may be responsible for transport of the high-affinity component of the carboxylate form of CPT-11.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bohme M, Buchler M, Muller M, Keppler D (1993) Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett 333:193
Buchler M, Konig J, Brom M, Kartenbeck J, Spring H, Horie T, Keppler D (1996) cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem 271:15091
Chu X, Kato Y, Niinuma K, Sudo K, Hakusui H, Sugiyama Y (1997) Multispecific organic anion transporter (cMOAT) is responsible for biliary excretion of the camptothecin derivative irinotecan, CPT-11, and its metabolites in rats. J Pharmacol Exp Ther 281:304
Chu X, Kato Y Sugiyama Y (1997) Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res 57:1934
Cole SPC, Bhardwaj J, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650
Fernandez-Checa JC, Takikawa H, Horie T, Ookhtens M, Kaplowitz N (1992) Canalicular transport of reduced glutathione in normal and mutant Eisai hyperbilirubinemic rats. J Biol Chem 267:1667
Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54:723
Gupta E, Safa AR, Wang X, Ratain MJ (1996) Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res 56:1309
Hertzberg RR Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, Mong SM, Bartus JO, Johnson RK, Kingsbury WD (1989) Modification of the hydroxyl lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32:715
Higgins CF (1992) ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8:67
Hirohashi T, Niinuma K, Ito K, Suzuki H, Kume K, Shimizu T, Sugiyama Y (1996) Characterization of ATP-dependent organic anion transport system on rat canalicular membrane maintained in EHBR. Hepatology 24:203A
Ito K, Suzuki H, Hirohashi T, Kume K, Shimizu T, Sugiyama Y (1997) Molecular cloning of canalicular multispecific organic anion transporter (cMOAT) whose expression is defective in mutant rats with hereditary conjugated hyperbilirubinemia (EHBR). Am J Physiol 272:G16
Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D (1994) ATP-dependent transport of glutathione S-conjugates by the multi-drug resistance-associated protein. Cancer Res 54:4833
Kaneda N, Nagata H, Furuta T, YokokuraT (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50:1715
Leier I, Jedlitschky G, Buchholz U, Center M, Cole SPC, Deeley RG, Keppler D (1996) ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Biochem J 314:433
Loe DW, Almquist KC, Cole SPC, Deeley RG (1996) ATP-dependent 17β-estradiol 17-(β-D-glucuronide) transport by multi-drug resistance protein (MRP). J Biol Chem 271:9683
Loe DW, Almquist KC, Deeley RG, Cole SPC (1996) Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. J Biol Chem 271:675
Masuda M, Iizuka Y, Yamazaki M, Nishigaki R, Kato Y, Niinuma K, Suzuki H, Sugiyama Y (1997) Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res 57:3506
Narita M, Nagai E, Hagiwara H, Aburada M, Yokoi T, KamatakiT (1996) Inhibition of β-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydro-xycamptothecin) as a substrate. Xenobiotica 23:5
Niinuma K, Takenaka O, Horie T, Kobayashi K, Kato Y, Suzuki, H, Sugiyama Y (1997) Kinetic analysis of the primary active transport of conjugated metabolites across the bile canalicular membrane: comparative study of S-(2,4-dinitrophenyl)-glutathione and 6-Hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridyl-methyl) benzothiazole glucuronide. J Pharmacol Exp Ther 282:866
Paulusma CC, Bosma PJ, Zaman GJR, Bakker CTM, Otter M, Scheffer GL, Scheper RJ, Borst P, Elferink RPJO (1996) Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271: 1126
Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen T, Hendricks C, Rock MK, Donehower RC (1994) Phase I and pharmacological study of novel topoisomerase I inhibitor 7-ethyl-10-[4-(l-piperidino)-l-piperidino] carbonyloxy-camptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54:427
Sasaki Y, Yoshida Y, Sudoh K, Hakusui H, Fujii H, Ohtsu T, Wakita H, Igarashi T, Itoh K (1997) Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn J Cancer Res 86:111
Takasuna K, Kasai Y, Kitano Y, Mori K, Kobayashi R, Hagiwara T, Kakihata K, Hirohashi M, Nomura M, Nagai E, Kamataki T (1995) Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn J Cancer Res 86:978
Takenaka O, Horie T, Kobayashi K, Suzuki H, Sugiyama Y (1995) Kinetic analysis of hepatobiliary transport for conjugated metabolites in the perfused liver of mutant rats (EHBR) with hereditary conjugated hyperbilirubinemia. Pharm Res 12:1746
Yamazaki M, Suzuki H, Sugiyama Y (1996) Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res 13:497
Author information
Authors and Affiliations
Additional information
Work presented at the 13th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium, “Strategic Cross Talk between Major Oncology Groups/Clinical Pharmacology in Cancer Chemotherapy,” 17–18 October 1997, Nagoya, Japan
Rights and permissions
About this article
Cite this article
Sugiyama, Y., Kato, Y. & Chu, Xy. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother Pharmacol 42 (Suppl 1), S44–S49 (1998). https://doi.org/10.1007/s002800051078
Issue Date:
DOI: https://doi.org/10.1007/s002800051078